237 related articles for article (PubMed ID: 25759110)
1. From benzalkonium chloride-preserved Latanoprost to Polyquad-preserved Travoprost: a 6-month study on ocular surface safety and tolerability.
Rossi GC; Scudeller L; Rolle T; Pasinetti GM; Bianchi PE
Expert Opin Drug Saf; 2015 May; 14(5):619-23. PubMed ID: 25759110
[TBL] [Abstract][Full Text] [Related]
2. Long-term effect of BAK-free travoprost on ocular surface and intraocular pressure in glaucoma patients after transition from latanoprost.
Aihara M; Otani S; Kozaki J; Unoki K; Takeuchi M; Minami K; Miyata K
J Glaucoma; 2012 Jan; 21(1):60-4. PubMed ID: 21278589
[TBL] [Abstract][Full Text] [Related]
3. Effect of benzalkonium chloride-free travoprost on intraocular pressure and ocular surface symptoms in patients with glaucoma previously on latanoprost: an open-label study.
Lopes JF; Hubatsch DA; Amaris P
BMC Ophthalmol; 2015 Nov; 15():166. PubMed ID: 26563363
[TBL] [Abstract][Full Text] [Related]
4. Ocular surface tolerability of prostaglandin analogs in patients with glaucoma or ocular hypertension.
Whitson JT; Trattler WB; Matossian C; Williams J; Hollander DA
J Ocul Pharmacol Ther; 2010 Jun; 26(3):287-92. PubMed ID: 20578283
[TBL] [Abstract][Full Text] [Related]
5. Effects of SofZia-preserved travoprost and benzalkonium chloride-preserved latanoprost on the ocular surface -- a multicentre randomized single-masked study.
Aihara M; Oshima H; Araie M;
Acta Ophthalmol; 2013 Feb; 91(1):e7-e14. PubMed ID: 23241328
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the toxicity profile of benzalkonium chloride-preserved tafluprost and SofZia-preserved travoprost applied to the ocular surface.
Kanamoto T; Kiuchi Y; Tanito M; Mizoue S; Naito T; Teranishi S; Hirooka K; Rimayanti U;
J Ocul Pharmacol Ther; 2015 Apr; 31(3):156-64. PubMed ID: 25710276
[TBL] [Abstract][Full Text] [Related]
7. Comparison of a travoprost BAK-free formulation preserved with polyquaternium-1 with BAK-preserved travoprost in ocular hypertension or open-angle glaucoma.
Gandolfi S; Paredes T; Goldberg I; Coote M; Wells A; Volksone L; Pillai MR; Stalmans I; Denis P;
Eur J Ophthalmol; 2012; 22(1):34-44. PubMed ID: 22167541
[TBL] [Abstract][Full Text] [Related]
8. Effect of Switching to Travoprost Preserved With SofZia in Glaucoma Patients With Chronic Superficial Punctate Keratitis While Receiving BAK-preserved Latanoprost.
Aihara M; Ikeda Y; Mizoue S; Arakaki Y; Kita N; Kobayashi S;
J Glaucoma; 2016 Jun; 25(6):e610-4. PubMed ID: 25967526
[TBL] [Abstract][Full Text] [Related]
9. Ocular surface tolerability of prostaglandin analogs and prostamides in patients with glaucoma or ocular hypertension.
Crichton AC; Vold S; Williams JM; Hollander DA
Adv Ther; 2013 Mar; 30(3):260-70. PubMed ID: 23475405
[TBL] [Abstract][Full Text] [Related]
10. Ocular Surface Disease with BAK preserved Travoprost and Polyquaternium 1(Polyquad) preserved Travoprost.
Kumar S; Singh T; Ichhpujani P; Vohra S
Rom J Ophthalmol; 2019; 63(3):249-256. PubMed ID: 31687627
[No Abstract] [Full Text] [Related]
11. The use of benzalkonium chloride in topical glaucoma treatment: An investigation of the efficacy and safety of benzalkonium chloride-preserved intraocular pressure-lowering eye drops and their effect on conjunctival goblet cells.
Nagstrup AH
Acta Ophthalmol; 2023 Dec; 101 Suppl 278():3-21. PubMed ID: 38037546
[TBL] [Abstract][Full Text] [Related]
12. Effects of polyquaternium- and benzalkonium-chloride-preserved travoprost on ocular surfaces: an impression cytology study.
Sezgin Akçay Bİ; Güney E; Bozkurt TK; Topal CS; Akkan JC; Ünlü C
J Ocul Pharmacol Ther; 2014 Sep; 30(7):548-53. PubMed ID: 24901262
[TBL] [Abstract][Full Text] [Related]
13. 24-hour efficacy of travoprost/timolol BAK-free versus latanoprost/timolol fixed combinations in patients insufficiently controlled with latanoprost.
Konstas AG; Voudouragkaki IC; Boboridis KG; Haidich AB; Paschalinou E; Giannopoulos T; Dragoumis ND; Makridis AK; Kahook MY
Adv Ther; 2014 Jun; 31(6):592-603. PubMed ID: 24919410
[TBL] [Abstract][Full Text] [Related]
14. Comparison of BAK-preserved latanoprost and polyquad-preserved travoprost on ocular surface parameters in patients with glaucoma and ocular hypertension.
Muz OE; Dagdelen K; Pirdal T; Guler M
Int Ophthalmol; 2021 Nov; 41(11):3825-3835. PubMed ID: 34263385
[TBL] [Abstract][Full Text] [Related]
15. Late-day intraocular pressure-lowering efficacy and tolerability of travoprost 0.004% versus bimatoprost 0.01% in patients with open-angle glaucoma or ocular hypertension: a randomized trial.
DuBiner HB; Hubatsch DA
BMC Ophthalmol; 2014 Nov; 14():151. PubMed ID: 25432143
[TBL] [Abstract][Full Text] [Related]
16. Polyquad-preserved travoprost/timolol, benzalkonium chloride (BAK)-preserved travoprost/timolol, and latanoprost/timolol in fixed combinations: a rabbit ocular surface study.
Liang H; Brignole-Baudouin F; Pauly A; Riancho L; Baudouin C
Adv Ther; 2011 Apr; 28(4):311-25. PubMed ID: 21424577
[TBL] [Abstract][Full Text] [Related]
17. Polyquaternium-1-Preserved Travoprost 0.003% or Benzalkonium Chloride-Preserved Travoprost 0.004% for Glaucoma and Ocular Hypertension.
Peace JH; Ahlberg P; Wagner M; Lim JM; Wirta D; Branch JD
Am J Ophthalmol; 2015 Aug; 160(2):266-274.e1. PubMed ID: 25935098
[TBL] [Abstract][Full Text] [Related]
18. Comparative in vitro toxicology study of travoprost polyquad-preserved, travoprost BAK-preserved, and latanoprost BAK-preserved ophthalmic solutions on human conjunctival epithelial cells.
Brignole-Baudouin F; Riancho L; Liang H; Baudouin C
Curr Eye Res; 2011 Nov; 36(11):979-88. PubMed ID: 21999224
[TBL] [Abstract][Full Text] [Related]
19. Duration of IOP reduction with travoprost BAK-free solution.
Gross RL; Peace JH; Smith SE; Walters TR; Dubiner HB; Weiss MJ; Ochsner KI
J Glaucoma; 2008; 17(3):217-22. PubMed ID: 18414108
[TBL] [Abstract][Full Text] [Related]
20. Switching from concomitant latanoprost 0.005% and timolol 0.5% to a fixed combination of travoprost 0.004%/timolol 0.5% in patients with primary open-angle glaucoma and ocular hypertension: a 6-month, multicenter, cohort study.
Rossi GC; Pasinetti GM; Bracchino M; Bucarelli M; Franchin S; Cerqueti P; Bellini R; Caravati C; Celesia L; Clemente A; Tinelli C
Expert Opin Pharmacother; 2009 Aug; 10(11):1705-11. PubMed ID: 19601697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
